GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Vaso Corporation (OTCPK:VASO) » Definitions » Asset Turnover

Vaso (VASO) Asset Turnover : 0.26 (As of Mar. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Vaso Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Vaso's Revenue for the three months ended in Mar. 2024 was $18.74 Mil. Vaso's Total Assets for the quarter that ended in Mar. 2024 was $72.60 Mil. Therefore, Vaso's Asset Turnover for the quarter that ended in Mar. 2024 was 0.26.

Asset Turnover is linked to ROE % through Du Pont Formula. Vaso's annualized ROE % for the quarter that ended in Mar. 2024 was -17.90%. It is also linked to ROA % through Du Pont Formula. Vaso's annualized ROA % for the quarter that ended in Mar. 2024 was -6.46%.


Vaso Asset Turnover Historical Data

The historical data trend for Vaso's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaso Asset Turnover Chart

Vaso Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.44 1.33 1.47 1.28 1.10

Vaso Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.27 0.29 0.27 0.30 0.26

Competitive Comparison of Vaso's Asset Turnover

For the Health Information Services subindustry, Vaso's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vaso's Asset Turnover Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Vaso's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Vaso's Asset Turnover falls into.



Vaso Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Vaso's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=81.024/( (71.645+75.757)/ 2 )
=81.024/73.701
=1.10

Vaso's Asset Turnover for the quarter that ended in Mar. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=18.738/( (75.757+69.444)/ 2 )
=18.738/72.6005
=0.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Vaso  (OTCPK:VASO) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Vaso's annulized ROE % for the quarter that ended in Mar. 2024 is

ROE %**(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-4.692/26.2105
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-4.692 / 74.952)*(74.952 / 72.6005)*(72.6005/ 26.2105)
=Net Margin %*Asset Turnover*Equity Multiplier
=-6.26 %*1.0324*2.7699
=ROA %*Equity Multiplier
=-6.46 %*2.7699
=-17.90 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Vaso's annulized ROA % for the quarter that ended in Mar. 2024 is

ROA %(Q: Mar. 2024 )
=Net Income/Total Assets
=-4.692/72.6005
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-4.692 / 74.952)*(74.952 / 72.6005)
=Net Margin %*Asset Turnover
=-6.26 %*1.0324
=-6.46 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Vaso Asset Turnover Related Terms

Thank you for viewing the detailed overview of Vaso's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Vaso (VASO) Business Description

Traded in Other Exchanges
N/A
Address
137 Commercial Street, Unit 200, Plainview, NY, USA, 11803
Vaso Corporation is a medical technology company. It provides diverse product and service categories, including noninvasive monitoring and therapeutic devices, diagnostic imaging equipment, and information technology for enterprises and clinical customers. The company currently operates in three distinct business units namely IT; Professional sales and Equipment. It generates maximum revenue from the IT segment. IT segment focuses on healthcare IT and managed network technology services.
Executives
Leon Dembo director 137 COMMERCIAL STREET, SUITE 200, PLAINVIEW NY 11803
Janey Moen director 137 COMMERCIAL STREET, SUITE 200, PLAINVIEW NY 11803
Jun Ma director C/O VASOMEDICAL, INC., 180 LINDEN AVENUE, WESTBURY NY 11590
Edgar Rios director 1650 TYSONS BOULEVARD, SUITE 900, MCLEAN VA 22102
Michael Beecher officer: Chief Financial Officer C/O DIRECT INSITE CORP, 80 ORVILLE DRIVE, BOHEMIA NY 11716
Joshua Markowitz director 3131 PRINCETON PIKE, BLDG. 3D, SUITE 200, LAWRENCEVILLE NJ 08648
Jonathan P Newton officer: Vice Pres Finance & Controller 152 RICHMOND AVENUE, AMITYVILLE NY 11701
Peter C Castle director C/O NETWOLVES CORP, 4002 EISENHOWER BLVD, TEMPA FL 33634
David H Lieberman director 3061 INDUSTRY DR, LANCASTER PA 17603
Behnam Movaseghi director C/O KERNS MANUFACTURING CORPORATION, 37-14 29TH STREET, LONG ISLAND CITY NY 11101
Nelson Randall Hill officer: Senior Vice President 3880 EAST COUNTY HIGHWAY 30A, UNIT 201, SANTA ROSA BEACH FL 24159
William Edward Dempsey director 52 PARK AVENUE, SANDYMOUNT L2 DUBLIN 4
David Tarachand Singh officer: Chief Financial Officer C/O VASOMEDICAL, INC., 180 LINDEN AVENUE, WESTBURY NY 11590
Joseph Giacalone director
Derek Enlander director 88C UNION AVENUE, CENTER MORICHES NY 11934